Skip to content

Study · Observational study · 2026

12 results

Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.

Chunduri S, Bidaoui G, Hussein MH, Patel M, Abdelmaksoud A, Mohamed M, Attia A, Tatum D, Borgi J, Toraih EA

Cardiovascular drugs and therapy12 Sept 2025Cited by 2 (Europe PMC)

PMID40938549 (opens in a new tab)DOI10.1007/s10557-025-07757-3 (opens in a new tab)PepBankPUB-40938549
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with a lower incidence of cerebrovascular disease than semaglutide (11.8% vs. 17.5%; HR = 0.831).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer cerebrovascular events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCerebrovascular disease
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    11.8%
    tirzepatide
    Incidence
    17.5%
    semaglutide
    Hazard ratio
    0.831
    tirzepatide versus semaglutide

    Source sentences

    Summary
    reduced incidence of cerebrovascular disease (11.8% vs. 17.5%; HR = 0.831)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with a lower incidence of cerebral infarction than semaglutide (4.6% vs. 7.3%; HR = 0.788).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer cerebral infarctions (strokes) than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCerebral infarction
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    4.6%
    tirzepatide
    Incidence
    7.3%
    semaglutide
    Hazard ratio
    0.788
    tirzepatide versus semaglutide

    Source sentences

    Summary
    cerebral infarction (4.6% vs. 7.3%; HR = 0.788)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with a lower incidence of cerebral occlusion without infarction than semaglutide (6.8% vs. 10.4%; HR = 0.838).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer cerebral artery blockages without stroke than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCerebral occlusion without infarction
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    6.8%
    tirzepatide
    Incidence
    10.4%
    semaglutide
    Hazard ratio
    0.838
    tirzepatide versus semaglutide

    Source sentences

    Summary
    cerebral occlusion without infarction (6.8% vs. 10.4%; HR = 0.838)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with fewer major adverse cardiovascular events than semaglutide (39.7% vs. 49.5%; HR = 0.911).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer major heart and vessel events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse cardiovascular events (MACE)
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    39.7%
    tirzepatide
    Incidence
    49.5%
    semaglutide
    Hazard ratio
    0.911
    tirzepatide versus semaglutide

    Source sentences

    Summary
    major adverse cardiovascular events (MACE) (39.7% vs. 49.5%; HR = 0.911)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with fewer myocardial infarctions than semaglutide (7.0% vs. 10.8%; HR = 0.838).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer heart attacks than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMyocardial infarction
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    7%
    tirzepatide
    Incidence
    10.8%
    semaglutide
    Hazard ratio
    0.838
    tirzepatide versus semaglutide

    Source sentences

    Summary
    myocardial infarction (7.0% vs. 10.8%; HR = 0.838)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with less acute coronary disease than semaglutide (1.1% vs 2.3%; HR = 0.691).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to less acute coronary disease than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAcute coronary disease
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    1.1%
    tirzepatide
    Incidence
    2.3%
    semaglutide
    Hazard ratio
    0.691
    tirzepatide versus semaglutide

    Source sentences

    Summary
    acute coronary disease (1.1% vs 2.3%; HR = 0.691)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  7. 07HumanObservational studySafety outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with lower rates of surgical site infection than semaglutide, but this was not statistically significant after adjustment.

    In plain wordsIn adults with type 2 diabetes after bypass surgery, wound infection was lower with tirzepatide than semaglutide, but the difference did not hold after adjustment.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSurgical site infection
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Adverse events · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While tirzepatide was associated with lower rates of surgical site infection, venous thrombosis, and CABG-specific complications, only venous thrombosis remained statistically significant after adjustment (adjusted p = 0.021).
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  8. 08HumanObservational studySafety outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with lower rates of venous thrombosis than semaglutide, which remained significant after adjustment (adjusted p = 0.021).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide was linked to fewer venous blood clots than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseVenous thrombosis
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Adjusted p
    0.021
    venous thrombosis

    Source sentences

    Summary
    While tirzepatide was associated with lower rates of surgical site infection, venous thrombosis, and CABG-specific complications, only venous thrombosis remained statistically significant after adjustment (adjusted p = 0.021).
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  9. 09HumanObservational studySafety outcome

    In adults with type 2 diabetes who had CABG, tirzepatide was associated with lower rates of CABG-specific complications than semaglutide, but this was not statistically significant after adjustment.

    In plain wordsIn adults with type 2 diabetes after bypass surgery, bypass-specific complications were lower with tirzepatide than semaglutide, but the difference did not hold after adjustment.

    Peptide
    Tirzepatide
    Outcome
    No significant changeCABG-specific complications
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    While tirzepatide was associated with lower rates of surgical site infection, venous thrombosis, and CABG-specific complications, only venous thrombosis remained statistically significant after adjustment (adjusted p = 0.021).
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  10. 10HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, 3-year readmission was lower with tirzepatide than with semaglutide (16.4% vs. 23.4%; HR = 0.871), significant after adjustment (adjusted p = 0.002).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, tirzepatide users were less often readmitted within 3 years than semaglutide users.

    Peptide
    Tirzepatide
    Outcome
    Decrease3-year readmission
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Measurements

    Incidence
    16.4%
    tirzepatide
    Incidence
    23.4%
    semaglutide
    Hazard ratio
    0.871
    tirzepatide versus semaglutide

    Source sentences

    Summary
    3-year readmission (16.4% vs. 23.4%; HR = 0.871)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  11. 11HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, 3-year all-cause mortality was lower with tirzepatide than with semaglutide (1.9% vs. 4.7%; HR = 0.595), significant after adjustment (adjusted p = 0.002).

    In plain wordsIn adults with type 2 diabetes after bypass surgery, fewer tirzepatide users died within 3 years than semaglutide users.

    Peptide
    Tirzepatide
    Outcome
    Decrease3-year all-cause mortality
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Mortality
    1.9%
    tirzepatide
    Mortality
    4.7%
    semaglutide
    Hazard ratio
    0.595
    tirzepatide versus semaglutide

    Source sentences

    Summary
    mortality (1.9% vs. 4.7%; HR = 0.595)
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.
  12. 12HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who had CABG, Kaplan-Meier analysis confirmed a sustained survival benefit with tirzepatide compared with semaglutide.

    In plain wordsIn adults with type 2 diabetes after bypass surgery, survival curves favored tirzepatide over semaglutide over time.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSurvival (Kaplan-Meier)
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Kaplan-Meier analysis confirmed sustained survival benefit.
    1 context sentence
    Summary · context
    We conducted a retrospective analysis using the TriNetX global research network, identifying 226,742 adults with T2DM who underwent isolated CABG between 2022 and 2024. Among these, 3,669 received tirzepatide and 19,521 received semaglutide. After 1:1 propensity score matching, 3,667 matched pairs were analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.